68Ga-citrate PET/MR Imaging for Glioma

68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

Inclusion Criteria:

• World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery
• Age >= 18 yrs.
• Karnofsky performance status of >= 60
• Ability to understand a written informed consent document, and the willingness to sign it.

Cohort A:

- Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by immunohistochemistry of tissue biopsy

Cohort B:

- Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

Exclusion Criteria:

• Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)
• Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)